Understanding Type 1 Diabetes as an Autoimmune Disease

Type 1 diabetes (T1D) is not merely a metabolic disorder—it is a chronic autoimmune condition in which the body’s immune system launches a misguided attack against its own insulin-producing beta cells in the pancreas. This autoimmune assault leads to an absolute deficiency of insulin, requiring lifelong insulin therapy for survival. For decades, researchers have worked to piece together the complex cascade of immune events that trigger beta cell destruction, and the Juvenile Diabetes Research Foundation (JDRF) has been at the forefront of this effort.

Understanding the autoimmune nature of T1D is critical because it opens the door to interventions that can halt or reverse the disease process before all beta cells are lost. JDRF’s strategic investments in immunology, genetics, and clinical trials have transformed our understanding of how T cells, B cells, and autoantibodies collaborate to cause T1D. Their work has also laid the foundation for groundbreaking therapies like teplizumab—the first drug shown to delay the onset of T1D—and for screening programs that identify at-risk individuals years before symptoms appear.

JDRF: A Legacy of Focused Research Funding

Founded in 1970 by parents of children with T1D, JDRF is the world’s largest charitable funder of type 1 diabetes research. Unlike organizations that fund diabetes broadly, JDRF zeroes in on T1D with a mission to cure, prevent, and treat the disease. Over the past five decades, the foundation has channeled more than $2 billion into research, with a substantial portion dedicated to unraveling the autoimmune mechanisms at the heart of T1D.

JDRF’s grant-making strategy prioritizes high-risk, high-reward projects that often struggle to attract funding from traditional sources. They have funded many of the seminal studies that identified the key immune players in T1D, developed animal models for pre-clinical testing, and accelerated the translation of basic immunology into clinical trials. Their commitment to a cure-driven approach has made them a driving force behind major advances in immunotherapy, beta cell regeneration, and immune tolerance.

Key Research Areas JDRF Has Championed

Mechanisms of Autoimmune Attack: T Cells and Autoantibodies

T cells are the primary executioners of beta cell destruction in T1D. Autoreactive CD4+ helper T cells and CD8+ killer T cells recognize specific peptides from insulin, GAD65, IA-2, and other beta cell proteins as foreign. JDRF-funded research has painstakingly characterized these T cell epitopes and the molecular triggers that cause thymic tolerance to fail. Studies have shown that a combination of genetic predisposition (especially HLA risk alleles) and environmental triggers—such as viral infections—can tip the balance toward autoimmunity.

In parallel, JDRF has supported the discovery and validation of autoantibodies as biomarkers. The presence of two or more islet autoantibodies (insulin autoantibody, GADA, IA-2A, or ZnT8A) in a child is now recognized as stage 1 T1D, even before blood glucose becomes abnormal. This classification, developed through JDRF-funded collaborative networks like TrialNet, allows researchers to intervene at presymptomatic stages. Over TrialNet has screened more than 200,000 relatives of people with T1D, providing unprecedented data on the natural history of the autoimmune process.

Environmental Triggers and the Hygiene Hypothesis

JDRF has also funded epidemiological studies exploring why T1D incidence has risen dramatically in recent decades. The hygiene hypothesis suggests that reduced microbial exposure in early childhood may impair proper immune regulation. JDRF-supported projects like the TEDDY study (The Environmental Determinants of Diabetes in the Young) follow children with high genetic risk from birth, collecting data on diet, infections, gut microbiome, and stress. Results have linked early enterovirus infections and vitamin D levels to increased risk—information that could guide prevention strategies.

Biomarkers for Early Detection and Staging

JDRF’s investment in biomarkers extends beyond autoantibodies. They have funded research into genetic risk scores that combine hundreds of variants to predict T1D risk more accurately than HLA typing alone. Epigenetic markers, metabolomics profiles, and proteomic signatures are being evaluated in JDRF-funded consortia. The goal is to develop a multi-analyte blood test that can detect the autoimmune process years before symptoms develop, enabling enrollment in primary prevention trials.

This work culminated in the 2019 FDA approval of teplizumab, a CD3-directed monoclonal antibody, which JDRF helped develop. Teplizumab was shown in a landmark JDRF-supported clinical trial to delay progression from stage 2 (autoantibodies plus dysglycemia) to stage 3 (clinical T1D) by an average of two years. This therapy, now sold as Tzield, represents the first-ever disease-modifying therapy for T1D—a direct payoff of decades of autoimmune research JDRF underwrote.

Immune Therapies: From Concept to Clinic

JDRF has funded a pipeline of immunomodulatory approaches:

  • Antigen-specific therapies: Designed to restore tolerance without broad immunosuppression. JDRF-backed trials of altered peptide ligands and oral insulin have shown promise in preserving residual beta cell function.
  • Costimulation blockade: Abatacept (CTLA4-Ig) reduced loss of beta cell function in a JDRF-funded trial by interfering with T cell activation.
  • Anti-cytokine therapy: Drugs targeting IL-1β, TNF-α, and IL-21 are being tested to dampen the inflammatory environment around islets.
  • Regulatory T cell (Treg) therapy: JDRF invested early in ex vivo expansion and infusion of autologous Tregs to rebalance the immune system. Early-phase trials are underway to assess safety and durability.

A major thrust of JDRF’s Research Strategy is the development of combination therapies that target multiple pathways simultaneously—such as a Treg-promoting drug plus an antigen-specific vaccine—to achieve lasting immune tolerance with minimal side effects.

Beta Cell Replacement and Regeneration

Understanding autoimmune destruction has also guided JDRF’s efforts to replace or regenerate beta cells. If the immune system can be prevented (or retrained) from attacking new beta cells, then islet transplantation or stem cell–derived beta cells could function without lifelong immunosuppression. JDRF has funded numerous projects aimed at generating beta cells from pluripotent stem cells and encapsulating them in biocompatible devices that hide them from immune attack.

One of the most successful JDRF-supported ventures is the collaboration with ViaCyte (now Vertex Pharmaceuticals) to develop an encapsulated stem cell product. Their first-generation device demonstrated safety and the ability to produce insulin in patients. Second-generation devices integrate immune-protective materials and are being tested in clinical trials. Recent advances in gene editing and immune evasion are now being applied to generate “universal donor” beta cells that avoid rejection even without encapsulation.

Induction of Immune Tolerance

Perhaps the most ambitious goal is achieving permanent immune tolerance—teaching the immune system to treat beta cells as “self.” JDRF has funded fundamental studies of central and peripheral tolerance mechanisms. For example, they supported research on thymic epithelial cells that express insulin and other self-antigens to delete autoreactive T cells. They also funded work on anti-CD3 therapy, which can re-educate T cells to become protective rather than destructive. The success of teplizumab and other CD3 antibodies is proof of concept that tolerance can be induced to delay disease. Current JDRF projects aim to extend the duration of these benefits and combine tolerance induction with beta cell restoration to offer a functional cure.

Impact on Clinical Practice and Patient Outcomes

JDRF’s contributions have moved beyond the laboratory bench. The foundation has been instrumental in changing clinical guidelines and insurance coverage for T1D immunotherapy. In 2022, based largely on JDRF-funded data, the American Diabetes Association updated its Standards of Medical Care to recommend screening for islet autoantibodies in relatives of people with T1D and to consider teplizumab therapy for eligible individuals. This shift means that thousands of families now have a path to intervention years before insulin dependence occurs.

Real-World Impact of Early Screening

Programs like TrialNet, ASK (Autoimmunity Screening for Kids), and the JDRF-supported Fr1da initiative in Germany are demonstrating that community-wide screening is feasible and cost-effective. Undiagnosed ketoacidosis, the leading cause of death in new-onset T1D, can be prevented when the autoimmune process is detected early. JDRF is now advocating for universal screening in pediatric primary care, modeled after newborn screening for metabolic disorders.

Economic and Quality-of-Life Benefits

Delaying clinical onset of T1D by even two years, as teplizumab does, reduces long-term complications and the burden of daily management. JDRF-funded health economics analyses have shown that prevention or delay yields savings of tens of thousands of dollars per patient over a lifetime. Moreover, families report improved psychosocial outcomes when they have time to prepare and access to monitoring resources.

Future Directions: Tailored Immunotherapies and a Cure

JDRF’s research portfolio continues to evolve. Key areas of focus for the next decade include:

  • Personalized medicine: Using genetic and biomarker profiles to select the right immunotherapy for each patient. For example, children with certain HLA types may respond best to antigen-specific therapy, while those with high T cell activation may benefit from costimulation blockade.
  • Precision immunology: Single-cell RNA sequencing and mass cytometry, funded by JDRF, are revealing rare T cell clones responsible for beta cell destruction. Targeting these exact clones with chimeric antigen receptor (CAR) Tregs could offer exquisite specificity.
  • Combination trials: The JDRF-supported Clinical Trial Network is coordinating multi-arm trials that test combinations of drugs (e.g., teplizumab plus abatacept) directly against single agents and placebo. Adaptive trial designs allow efficient exploration of hundreds of possibilities.
  • Gene editing for immune evasion: Projects are underway to create “stealth” beta cells by knocking out HLA class I molecules and overexpressing checkpoint ligands like PD-L1 using CRISPR. JDRF has funded labs working on these approaches because they could render stem cell–derived islets invisible to the immune system.
  • Prevention in the general population: JDRF is lobbying for infrastructure to screen all children at age 2–3 for islet autoantibodies, then randomize autoantibody-positive children to prevention strategies. Such a study would require massive funding, but JDRF is building public-private partnerships to make it a reality.

A JDRF blog post summarizing the teplizumab story underscores how the foundation’s long-term commitment to basic immunology directly resulted in a regulatable disease-modifying therapy. That success has energized the field and attracted additional investment from pharmaceutical companies and government agencies.

Challenges and the Road Ahead

Despite remarkable progress, significant hurdles remain. The immune system is highly redundant; blocking one pathway often leads to compensation by another. Achieving durable tolerance with a single agent is unlikely, which is why JDRF’s emphasis on combination therapies is appropriate. Another challenge is the narrow window of opportunity: by the time T1D is diagnosed clinically, most beta cells are already destroyed. Thus early detection via screening is not just helpful but necessary for any intervention to succeed. JDRF continues to push for expanded screening and for cost reductions in autoantibody testing.

Finally, translating laboratory findings into therapies that are affordable and accessible to all people with T1D—not just those in clinical trials—remains a priority. JDRF advocates at the federal level for coverage of screening and immunotherapies, and they educate policymakers about the value of prevention. They have also established the JDRF Industry Discovery and Development Partnership to de-risk early-stage projects that industry might otherwise ignore.

Conclusion: JDRF’s Indispensable Role

JDRF’s contributions to understanding the autoimmune nature of T1D are woven into nearly every major breakthrough of the past 50 years. From the discovery of autoantibody markers to the clinical validation of the first disease-slowing immunotherapy, the foundation has funded the people and ideas that made progress possible. Their willingness to invest in fundamental immunology at a time when few others did has paid enormous dividends. As research advances toward combination tolerance protocols, genetically engineered beta cells, and universal screening, JDRF remains the linchpin connecting academic discovery to real-world impact. For millions of families affected by T1D, that investment is the brightest hope for a future free from insulin dependence.